Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018 - UTU Research Portal

A1 Refereed original research article in a scientific journal

Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018

Authors: Kati Räisänen, Irma Koivula, Heikki Ilmavirta, Santeri Puranen, Teemu Kallonen, Outi Lyytikäinen, Jari Jalava

Publication year: 2019

Journal: Eurosurveillance

Journal name in source: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Volume: 24

Issue: 19

Number of pages: 3

ISSN: 1560-7917

DOI: https://doi.org/10.2807/1560-7917.es.2019.24.19.1900256

Web address : http://europepmc.org/abstract/med/31088601

Abstract

Ceftazidime-avibactam (CAZ-AVI) is a promising novel β-lactam-β-lactamase inhibitor combination with activity against multidrug-resistant (MDR) Enterobacteriaceae for which there are limited treatment options, e.g. those producing Klebsiella pneumoniae carbapenemases (KPC). According to the rapid risk assessment published by the European Centre for Disease Prevention and Control (ECDC) in June 2018, the emergence of CAZ-AVI resistance in Europe is a very rare phenomenon but an important cross-border threat that should be monitored carefully [1]. Here, we report the emergence of CAZ-AVI resistance in a KPC-2-producing K. pneumoniae strain and describe a mutation associated with the resistance.